Product Description
Mechanisms of Action: TK Inhibitor,ANG Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Deciphera
Company Location: WALTHAM MA 02451
Company CEO: Steven L. Hoerter
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Endometrial Cancer|Mixed Tumor, Malignant|Breast Cancer|Ovarian Cancer|Mixed Tumor, Mullerian|Carcinosarcoma|Mesothelioma
Phase 1: Adenocarcinoma|Breast Cancer|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DCC-2036-01-003 | P2 |
Terminated |
Ovarian Cancer|Mixed Tumor, Malignant|Mixed Tumor, Mullerian|Carcinosarcoma|Endometrial Cancer|Breast Cancer |
2022-05-23 |
|
| DCC-2036-01-004 | P2 |
Terminated |
Ovarian Cancer|Mesothelioma|Breast Cancer |
2022-05-01 |
|
| NCT02824575 | P1 |
Terminated |
Adenocarcinoma|Breast Cancer |
2021-12-27 |
|
| Ph+ CML With T315I Mutation | P1 |
Completed |
Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia |
2013-01-01 |